Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2033230642
JPRN-jRCT2033230642
Not yet recruiting
Phase 3

ong-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials

Hirano Takamitsu0 sites4 target enrollmentFebruary 16, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hirano Takamitsu
Enrollment
4
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hirano Takamitsu

Eligibility Criteria

Inclusion Criteria

  • •1\. Participated in an OAV101 clinical trial.
  • •2\. Written informed consent must be obtained before any assessment is performed.
  • •3\. Patient/Parent/legal guardian willing and able to comply with study procedures.

Exclusion Criteria

  • •There are no exclusion criteria for this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical TrialsSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
CTIS2024-511707-42-00ovartis Pharma AG160
Active, not recruiting
Phase 1
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-006781-21-BEovartis Pharma AG260
Active, not recruiting
Phase 1
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-006781-21-FRovartis Pharma AG260
Active, not recruiting
Phase 1
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-006781-21-DKovartis Pharma AG260
Not yet recruiting
Phase 3
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trialsspinal muscular atrophy1002830210029317
NL-OMON56701ovartis2